Want to see FBLG full AI Analyst Report?
Top Page
FibroBiologics, Inc.
(NASDAQ:FBLG)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.91
▼(-35.67% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by weak financial performance (no revenue, large ongoing losses, and substantial cash burn), which outweighs balance-sheet deleveraging progress. Technicals also point to continued weakness (below key moving averages with negative MACD). Corporate events add risk due to the Nasdaq delisting situation and continued financing needs, while valuation provides only limited support because earnings are negative and no dividend yield is provided.
Positive Factors
Deleveraging
Sharp deleveraging has materially strengthened the capitalization profile and reduced fixed financial obligations. Positive equity and lower total debt provide more flexibility than in 2024, potentially allowing a greater share of future funding to support research and development rather than debt service.
Negative Factors
No revenue and expanding losses
No commercial revenue means the company has not yet established a recurring economic engine to fund its operations. Losses remain substantially higher than in 2022, showing that development spending continues to outpace monetization and that profitability depends on successful future clinical and regulatory progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging
Sharp deleveraging has materially strengthened the capitalization profile and reduced fixed financial obligations. Positive equity and lower total debt provide more flexibility than in 2024, potentially allowing a greater share of future funding to support research and development rather than debt service.
Read all positive factors
FibroBiologics, Inc. (FBLG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.33M
Dividend YieldN/A
Average Volume (3M)145.94K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth22.10%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.00
Shares Outstanding6,658,193
10 Day Avg. Volume150,653
30 Day Avg. Volume145,935
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.63
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$6.00Price Target Upside325.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
FibroBiologics, Inc. Business Overview & Revenue Model
Company Description
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to addre...
FibroBiologics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -234.00K | -832.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.98M | -17.61M | -10.57M | -15.90M | -4.37M | -1.58M |
| Net Income | -18.14M | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
Balance Sheet | ||||||
| Total Assets | 7.93M | 9.62M | 16.45M | 11.82M | 4.82M | 468.00K |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 4.89M | 13.98M | 9.16M | 2.27M | 407.00K |
| Total Debt | 1.46M | 2.41M | 10.55M | 1.75M | 7.52M | 1.30M |
| Total Liabilities | 3.29M | 3.46M | 13.71M | 10.57M | 8.82M | 1.76M |
| Stockholders Equity | 4.64M | 6.16M | 2.73M | 1.25M | -4.00M | -1.29M |
Cash Flow | ||||||
| Free Cash Flow | -14.80M | -16.66M | -12.09M | -6.90M | -4.07M | -1.41M |
| Operating Cash Flow | -14.79M | -16.39M | -11.90M | -6.40M | -4.07M | -1.41M |
| Investing Cash Flow | -6.00K | -262.00K | -184.00K | -495.00K | 0.00 | 0.00 |
| Financing Cash Flow | 9.47M | 7.57M | 16.91M | 13.79M | 5.92M | 1.82M |
FibroBiologics, Inc. Technical Analysis
Negative
1.41
Price Trends
1.33
Negative
1.09
Negative
2.53
Negative
Market Momentum
-0.11
Positive
36.14
Neutral
30.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 1.41 is above the 20-day moving average (MA) of 1.09, above the 50-day MA of 1.33, and below the 200-day MA of 2.53, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 36.14 is Neutral, neither overbought nor oversold. The STOCH value of 30.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.
FibroBiologics, Inc. Risk Analysis
FibroBiologics, Inc. disclosed 66 risk factors in its most recent earnings report. FibroBiologics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
FibroBiologics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $12.86M | -17.97 | -5.60% | ― | ― | 46.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $10.58M | -1.14 | -47.22% | ― | -91.94% | 55.29% | |
44 Neutral | $5.06M | -0.32 | -394.24% | ― | ― | 90.37% | |
41 Neutral | $6.33M | -0.16 | -536.78% | ― | ― | 22.10% | |
41 Neutral | $807.40K | -0.03 | -1035.26% | ― | -62.17% | 85.37% |
* Healthcare Sector Average
FBLG
FibroBiologics, Inc.
0.95
-7.71
-89.02%
BLRX
Bioline RX Ltd Sponsored ADR
2.04
-1.72
-45.74%
CRIS
Curis
0.39
-30.81
-98.76%
SYBX
Synlogic
1.05
-0.71
-40.34%
LEXX
Lexaria Bioscience
3.08
-11.92
-79.47%
PCSA
Processa Pharmaceuticals
1.81
-5.96
-76.71%
FibroBiologics, Inc. Corporate Events
Private Placements and Financing
FibroBiologics Raises Capital via Convertible Debenture Financing
Positive
Oct 8, 2026
On October 7, 2026, FibroBiologics, Inc. entered into a securities purchase agreement with Peak One Opportunity Fund, L.P., leading to a private placement of a $1.2 million convertible debenture and 125,000 restricted common shares, which closed o...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
FibroBiologics Shareholders Approve Potential Warrant-Driven Share Issuance
Positive
Sep 18, 2026
FibroBiologics, Inc. reported that shareholders at a special meeting on September 17, 2026 approved the potential issuance of up to 8,448,980 shares of common stock upon exercise of existing warrants tied to prior financing agreements. The company...
Business Operations and StrategyPrivate Placements and Financing
FibroBiologics Announces Insider Private Placement Financing
Positive
Sep 15, 2026
On September 15, 2026, FibroBiologics entered into a securities purchase agreement with Chief Scientific Officer Hamid Khoja for a private placement of 298,508 shares of common stock and accompanying warrants at $1.675 per share and warrant, match...
Business Operations and StrategyExecutive/Board Changes
FibroBiologics Adds Leigh Steinberg to Board for Growth
Positive
Aug 24, 2026
On August 20, 2026, FibroBiologics appointed Leigh Steinberg as a Class II director to its board, with his term running until the 2028 annual meeting of stockholders, under standard non-employee director compensation and indemnification arrangemen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.